This article was downloaded by: [Brunel University] On: 12 December 2008 Access details: Access Details: [subscription number 773509782] Publisher Informa Healthcare Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK Disability & Rehabilitation Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713723807 High volume image guided injections in chronic Achilles tendinopathy Otto Chan a ; Dominic O'Dowd b ; Nat Padhiar b ; Dylan Morrissey b ; John King b ; Rosy Jalan b ; Nicola Maffulli c ; Tom Crisp b a Department of Imaging, The London Independent Hospital, London b Centre for Sports and Exercise Medicine, Mile End Hospital, London c Department of Trauma and Orthopaedic Surgery, Keele University School of Medicine, Staffordshire, UK First Published:2008 To cite this Article Chan, Otto, O'Dowd, Dominic, Padhiar, Nat, Morrissey, Dylan, King, John, Jalan, Rosy, Maffulli, Nicola and Crisp, Tom(2008)'High volume image guided injections in chronic Achilles tendinopathy',disability & Rehabilitation,30:20,1697 1708 To link to this Article: DOI: 10.1080/09638280701788225 URL: http://dx.doi.org/10.1080/09638280701788225 PLEASE SCROLL DOWN FOR ARTICLE Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden. The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.
Disability and Rehabilitation, 2008; 30(20 22): 1697 1708 High volume image guided injections in chronic Achilles tendinopathy OTTO CHAN 1, DOMINIC O DOWD 2, NAT PADHIAR 2, DYLAN MORRISSEY 2, JOHN KING 2, ROSY JALAN 2, NICOLA MAFFULLI 3 & TOM CRISP 2 1 Department of Imaging, The London Independent Hospital, Beaumont Square, London, 2 Centre for Sports and Exercise Medicine, Mile End Hospital, London, and 3 Department of Trauma and Orthopaedic Surgery, Keele University School of Medicine, Stoke-on-Trent, Staffordshire, UK Abstract Purpose. To determine the effectiveness of high volume image guided injections (HVIGI) for chronic Achilles tendinopathy. Methods. We included in the study 30 consecutive patients (mean age 37.2 years, range 24 58 years) with Achilles tendinopathy for a mean of 35.8 months (range 2 276 months) who had failed to improve after a three-month programme of eccentric loading of the gastro-soleus complex. Patients were injected with 10 ml of 0.5% Bupivacaine Hydrochloride, 25 mg Hydrocortisone acetate, and up to 40 ml of injectable normal saline. A study-specific questionnaire and the Victorian Institute of Sport Assessment Achilles tendon (VISA-A) were retrospectively administered to assess short- and long-term pain and functional improvement. Results. Some 21 patients (70%) responded. Patients reported significant short-term improvement at 4 weeks of both pain (mean change 50 mm, [SD 28, p 5 0.0001], from a mean of 76 mm [SD 18.2], to a mean of 25 mm [SD 23.3]), and function scores (mean change 51 mm, [SD 31.2, p 5 0.0001], from a mean of 78 mm [SD 20.8], to a mean of 27 mm [SD 28.4]). Patients also reported significant long-term improvement in symptoms using the VISA-A questionnaire (mean change 31.2 points, [SD ¼ 28, p 5 0.0001], from a mean of 44.8 points [SD 17.7], to a mean of 76.2 points [SD 24.6]) at a mean of 30.3 weeks from the injection. Conclusions. HVIGI significantly reduces pain and improves function in patients with resistant Achilles tendinopathy in the short- and long-term. Keywords: Achilles tendinopathy, image guided injection, neovascularization, eccentric loading Introduction Achilles tendinopathy is a common overuse injury with an incidence of 14.5% in army recruits, and a lifetime risk of 52% in former elite male distance runners [1,2] Up to 29% of Achilles tendinopathy patients may require surgery for Achilles tendinopathy, of which up to 31% do not participate in sport or vigorous physical activity [3,4]. Achilles tendinopathy has a multi-factorial aetiology [2,5], with training errors reported in up to 60 80% of such patients [6]. The aetiology of pain in tendinopathy is widely debated, with recent evidence that neo-vascularization and neo-innervation may be responsible [7 10]. Neo-vascularization is only present in patients with tendinopathy, and the area in which patients perceive most pain correlates with the area where most neo-vascularization occurs on power Doppler ultrasound scan (US) [10]. In Achilles tendinopathy, there is evidence of neural in-growth in conjunction with neo-vascularization, and a pilot study injecting a sclerosing agent, Polidocanol into and around the neo-vessels [8,11] significantly reduced pain in eight of 10 patients. A similar study of patellar tendinopathy, which has a similar histological picture to Achilles tendinopathy, gave equally encouraging results [12,13]. Correspondence: Nicola Maffulli, PhD, FRCS(Orth), Department of Trauma and Orthopaedic Surgery, University Hospital of North Staffordshire, Keele University School of Medicine, Stoke on Trent, Staffordshire ST4 7LN, UK. E-mail: n.maffulli@keele.ac.uk ISSN 0963-8288 print/issn 1464-5165 online ª 2008 Informa Healthcare USA, Inc. DOI: 10.1080/09638280701788225
1698 O. Chan et al. Injections of sclerosing substances close to the tendon seem to be remarkably safe. As Polidocanol is not on sale in our country, we hypothesized that a high volume image guided Achilles tendon injection (HVIGI) of normal saline would decrease the amount of pain perceived by Achilles tendinopathy patients, whilst at the same time improving daily functional ankle and Achilles movements. treatment and sporting participation. The VISA- A questionnaires were used to assess the longterm outcome for the effectiveness of HVIGI. Patients were asked to complete the first VISA-A questionnaire recalling the symptoms immediately prior to HVIGI, and the second for the symptoms on the day they returned the questionnaires (see Appendix). Methods Ethics Consultation with the Local Ethics Committee determined that ethics approval was not required. The London Independent Hospital Board granted consent for the study. Data was managed with strict confidentiality. The data were coded prior to analysis, and consent was implied if patients returned the postal questionnaire. Sample size No formal pre-intervention power calculation was performed. However, a post hoc power calculation was performed once results were obtained. Subjects All patients who received HVIGI between 2004 and 2006 for the management of Achilles tendinopathy were identified from the computerized radiology records at LIH. Inclusion and exclusion criteria Patients were included in the study if they were aged 18 65 and had been diagnosed with Achilles tendinopathy for at least three months before receiving HVIGI. They had to have undergone a programme of eccentric rehabilitation according to published guidelines [14]. Patients were excluded from the study if they had undergone Achilles tendon surgery, had concurrent musculoskeletal ankle problems, or had suffered a complete or partial tear of their Achilles tendon. Data collection method A total of 30 patients, (26 males and four females, mean age 37.2 years, range 24 58), satisfying the above criteria were identified. In February 2006, these patients were sent a study-specific questionnaire and two VISA-A questionnaires. The study questionnaire was designed to assess pain and function before and two weeks after HVIGI, and to obtain details of symptom history, Injection procedure Patients were positioned supine on a couch with their hip externally rotated, the knees flexed to 458 and the ankle plantigrade. Both Achilles tendons were scanned by a board certified musculo-skeletal radiologist (OC) using an US scanner (Sonoline Elegra; Siemens, Erlangen, Germany) equipped with a 13 MHZ probe in both the longitudinal and transverse planes throughout their length. The Achilles tendon was assessed for any thickening, degeneration, hypo-echogenic areas and presence of any other surrounding soft tissue abnormality. The thickness of the tendon was recorded in mm [15]. Power Doppler was used to ascertain the presence of intra-tendinous neo-vascularization (Figure 1a, 1b). The same board certified musculo-skeletal radiologist (OC) scanned and injected every patient. Verbal consent was obtained from each patient after having been given a detailed explanation of the procedure and possible outcome. Using an aseptic technique and assisted by a nurse, a 21 gauge needle attached to a 30 cm connecting tube was inserted under real-time ultrasound guidance between the anterior aspect of the Achilles tendon and Kager s fat pad. A mixture of 10 ml 0.5% Bupivacaine hydrochloride and 25 mg of Hydrocortisone acetate was injected, followed by 4 6 10 ml of injectable normal saline. The position of the needle and flow of fluid was monitored continuously by US during this phase, and the needle moved gently across the anterior aspect of the tendon. After HVIGI, the Achilles tendon was scanned again with power Doppler to assess whether any neo-vascularization remained (Figure 1c, 1d). Patients were allowed to walk on the injected leg immediately, but were advised strictly to refrain from high impact activity, such as running or jumping, for 72 h. They were also given information regarding possible steroid flare and risk of infection. After 72 h, they were instructed to restart heavy eccentric loading under the guidance of a chartered physiotherapist. Patients returned to their referring clinicians two weeks post injection for advice about further physiotherapy and returning to sport.
High volume image guided injections in chronic Achilles tendinopathy 1699 Statistics Descriptive statistics is given. Kolmogorov-Smirnov tests determined that the interval data from 100 mm VAS, and VISA-A questionnaires was normally distributed. Student s t-tests were therefore used to compare pain and function scores pre- and postinjection. All data were analysed with SPSS (Statistical Package for Social Scientists 1, version 12.0.1, SPSS 1 Inc USA). Figure 1. Images from the US prior to, during and after injection are presented. (a) Longitudinal view; (b) transverse view: Greyscale ultrasonography and power Doppler of an Achilles tendon showing abundant neo-vascularization before HVIGI; (c) transverse view: Grey-scale ultrasonography of the same Achilles tendon showing the needle ventral to it, while HVIGI is being performed; (d) longitudinal view: Grey-scale ultrasonography and power Doppler of the same Achilles tendon showing no remaining neo-vascularization after HVIGI. Results Subjects Thirty patients satisfying the above inclusion and exclusion criteria were identified. Two questionnaires were returned stating that the patients had moved from their given addresses. No followup address could be found for these patients, limiting the number of possible replies to 28 (male, female 26:4 mean age 37.20, range 24 58). Some 21 of 30 patients (70%) responded to the questionnaire. Subjects typically were athletically active to a high standard, in their third or fourth decade, had significant long-term symptoms, had abnormal findings on US examination, and had reduced sporting ability (Table I). Eight subjects competed professionally or at county level, while the remaining subjects were recreational or club participants with a mean sporting participation of 9.3 h per week. The mean duration of symptoms prior to injection was 35.8 months (range 3 276 months), with a mean sporting limitation of 29.1 months (range 0 276 months). At the time of injection, all patients had thickening of the Achilles tendon (mean 7.8 mm, range 5.4 15.0 mm), disordered intra-tendinous collagen structure, and evidence of neo-vascularization. Twenty of the 21 patients who responded complied with the recommended two-week eccentric loading program post HVIGI. The one patient who did not perform any eccentric loading exercises still rated the success of HVIGI as 60%, and was able to return to sport at their previous level. The procedure was effective in returning patients to sport. Nineteen of 21 patients returned to sport; 10 at their pre injury level, and nine at a reduced level. One patient was unable to return to sport, and perceived no improvement due to HVIGI treatment. No complications were reported as a result of the HVIGI. No patient experienced a rupture or tear of the Achilles tendon at follow-up, and no patient progressed to surgery.
1700 O. Chan et al. Follow-up results Short-term In asymptomatic patients, the VAS should score 0 mm [16]. At its highest, the VAS will score 100 mm for strong severe pain or dysfunction. In the short term (two weeks post-hvigi), the VAS pain scores showed a mean change of 50 mm (SD 28), from a mean of 76 mm (SD 18.2), to a mean of 25 mm (SD 23.3) (Figure 2). Using the same pre- HVIGI VAS, patients demonstrated a mid-term (mean 30.3 weeks) mean improvement of 47 mm (SD 39.2), with a mean VAS pain score of 28 mm (SD 32.1) at follow-up. The VAS function scores showed a mean functional gain of 51 mm (SD 31.3) 2 weeks post-hvigi. Pre-HVIGI, the mean score was 78 mm (SD 20.8). Post-HVIGI, the mean score was 27 mm (SD 28.4). All the VAS pain and function changes were statistically significant (p 5 0.001). (Figure 2). Long-term A VISA-A score of 100 points represents a normal asymptomatic Achilles [17]. Scores become progressively lower with worsening tendinopathy symptoms. Table I. Patient data and questionnaire feedback regarding activity levels and treatment. Sex Age when injected (years) Hours of sport per week pre-injury Sport level pre-injury Returned to sport? Percentage improvement due to injection Length of sporting limitation (months) Length of symptoms (months) M 29 5 10 Professional Yes - Same level 100 8 10 M 43 16 20 Professional Yes - Same level 100 12 12 M 37 11 15 Professional Yes - Same level 90 6 6 M 30 420 Professional Yes - Same level 82 0 19 M 27 420 Professional Yes - Same level 77 0 18 M 30 16 20 Professional No - Unable to 0 8 8 M 44 55 County Yes - Same level 100 72 72 M 42 11 15 County Yes - Reduced level 79 276 276 M 24 16 20 Club Yes - Reduced level 66 2 2 M 51 5 10 Club Yes - Reduced level 60 5 5 M 48 11 15 Club Yes - Reduced level 55 3 8 M 47 55 Club No - Haven t Tried 55 5 18 M 40 55 Club Yes - Reduced level 51 24 29 M 42 11 15 Club Yes - Same level 0 6 18 F 33 5 10 Recreational Yes - Reduced level 96 4 4 F 44 55 Recreational Yes - Same level 85 30 30 F 42 55 Recreational Yes - Reduced level 80 18 24 M 34 5 10 Recreational Yes - Reduced level 74 3 3 M 34 11 15 Recreational Yes - Reduced level 26 8 10 M 41 5 10 Recreational Yes - Same level 100 0 60 M 58 420 Other Yes - Same level 100 120 120 Figure 2. Mean retrospective VISA-A and VAS Pain and Function scores pre- and post- HVIGI. VISA-A follow-up was performed longterm.
High volume image guided injections in chronic Achilles tendinopathy 1701 The mean VISA-A score pre-hvigi was 44.8 points (SD 17.7), and post-hvigi was 76.2 points (SD 24.6) (Figure 3). This mean change of 31.5 points (SD 28) (p 5 0.001) occurred over a mean follow-up period of 30.3 weeks (SD 20.4). Using a two-sample equal variance power calculator, a sample size of 21 and the long-term VISA-A results, the power of the present study was calculated as 0.91. Discussion Patients were advised to commence eccentric loading post-hvigi [18]. With decreased pain, patients would be able to stress their tendons in a more physiological fashion, with the final aim to improve the tendon s collagen structure, so that the tendon would have been better able to deal with the stresses placed upon it [19 22]. The VISA-A questionnaire is a validated and reliable index for assessing Achilles tendinopathy [17]. VAS scores are validated and reliable measures of pain, and allowed direct comparison of treatment results with other studies [16]. US is cost effective, and accurately confirms clinical diagnoses of Achilles tendinopathy. It also enables precise guidance of the injections, ensuring that the desired area is injected [23]. Power Doppler is more sensitive than colour Doppler in imaging intratendinous neo-vascularization [24]. Neo-vascularization is often present in patients with tendinopathy [9,10], and is accompanied by nerve in-growth. Our hypothesized rationale behind the management modality we describe was that the high volume injection would produce local mechanical effects causing neo-vessels to stretch, break or occlude. By occluding and possibly breaking these neo-vessels, the accompanying nerve supply would also be damaged either by trauma or ischemia, therefore decreasing the pain in patients with resistant Achilles tendinopathy. We only assess neo-vascularity immediately following the injection, and we assumed that those patients who experienced a significant improvement in symptoms had a reduction in neo-vascularization. This is a weakness of the study. However, the disappearance of neovascularization immediately post-injection would confirm this hypothesis [25]. Other studies have divided results into VAS scores for patients who responded to treatment and those who did not [11,12,21,22]. To obtain a more complete picture, we have grouped all VAS scores regardless of treatment response. The mean VISA-A change in our patients was 31.5 points (p 5 0.001). We believe that this change is clinically relevant, as 19 of the 21 patients returned to a higher level of sport, reflecting the promising nature of HVIGI as a management modality for resistant Achilles tendinopathy. The slope of the pre-hvigi trend line in Figure 3 highlights the wide range of patient symptoms prior to the injection. On the other hand, the much flatter post-hvigi trend line suggests that most patients had improved to a similar level at follow-up. Therefore, patients with low VISA-A scores, and hence more severe symptoms, had the same chance of recovery as those patients with an initially high VISA-A score. The VAS pain results reflect closely those from similar studies examining the effects of sclerosing agents on neo-vascularization and pain [11,12]. One such study by Ohberg et al. returned a mean improvement in VAS pain of 52.7 mm at follow-up. Our results are fractionally lower at 50 mm. However, Ohberg et al. s patients received up to four injections, whereas our patients had only one injection: repeating the injections may yield better results. It remains to be ascertained whether a difference of 2 mm on the VAS pain scale is clinically and functionally relevant. Changes in VAS pain are again promising when comparing HVIGI to studies evaluating eccentric loading. Using eccentric loading, Fahlstrom et al. found a mean pain VAS improvement of 55.6 mm at 6 weeks follow-up in patients who responded to treatment [21]. We found a similar decline in patients pain (50 mm), but only Figure 3. VISA-A score of each patient before and after HVIGI treatment. Lines of best fit highlight the trends for the VISA-A scores.
1702 O. Chan et al. at two-week follow-up, and including patients who did not improve. However, our results are in a smaller number of patients, and an eccentric loading program was used post-hvigi. Eccentric loading is presently regarded as the corner stone of Achilles tendinopathy management, and should remain so at present, although we acknowledge that it may not be as effective as previously reported [14]. All of our patients were athletes (Table I), and all but two returned to their sport. However, a greater number of professionals and elite athletes returned to their pre-injury level of sport compared to athletes at a lesser level of participation. We recently reported that, following surgery for Achilles tendinopathy, athletes have a greater chance of an uncomplicated and quicker recovery compared to non-athletes [26]. The reason is undoubtedly multifactorial, but professional and elite athletes likely receive more structured rehabilitation, and are more motivated to return to their previous sporting level. The mean difference of 6.76 months between the duration of symptoms and length of sporting limitation was not unexpected. At ultrasound, areas of tendinopathy can be evident for some time before pain occurs, and start to impair lower limb function [27]. During this window, patients are often able to exercise through pain, possibly causing more tendon damage. We are fully aware of the limitations of the present study. For example, as ours is the only centre offering this procedure, and as HVIGI is not offered within the NHS, only patients attending the independent sector received this treatment. This therefore limited patients numbers, and the size of our study. Also, it biases the type of patients who were offered HVIGI. Postal questionnaires have a notoriously low response rate. At a 70% return rate, we are aware that an incomplete picture may have been shown. Efforts were made to limit this factor by a follow-up call to patients four weeks after questionnaires were sent out. Every five years, the population of London changes by up to one third [28]. This may have impacted on our results, as two patients had moved and could not be traced for follow-up. Finally, this is a retrospective study which required some patients to remember the pain and function limitation for their Achilles tendinopathy as far back as 79 weeks. This may have induced recall bias, possibly making some of the feedback inaccurate. Further studies examining the mechanism of pain reduction and functional return following HVIGI are required. A prospective study with follow-up estimates of the amount of neo-vascularization would more accurately evaluate the potential of this modality as an alternative to surgery. Also, neovascularization in the Achilles tendon could be assessed, and measured in a prospective fashion [29]. We stress that this is to be considered a preliminary study, and the good results obtained using HVIGI should not be overplayed until further research with larger sample sizes has been conducted. Conclusion In conclusion, this preliminary study indicates that HVIGI significantly reduce pain and improve short and long-term function in patients with chronic Achilles tendinopathy, regardless of their level of symptoms. HVIGI is safe and relatively inexpensive, with the potential to offer an alternative management option before surgery, aiding a quicker return to sport. Acknowledgements Many thanks are given to the management and staff of the London Independent Hospital for their support. The help of Mr Faisal Khan BSC is gratefully acknowledged. There were no competing interests and no funding was received. References 1. Kujala UM, Sarna S, Kaprio J. Cumulative incidence of Achilles tendon rupture and tendinopathy in male former elite athletes. Clin J Sport Med 2005;15(3):133 135. 2. Mahieu NN, Witvrouw E, Stevens V, Van TD, Roget P. Intrinsic risk factors for the development of Achilles tendon overuse injury: A prospective study. Am J Sports Med 2006;34(2):226 235. 3. Paavola M, Kannus P, Paakkala T, Pasanen M, Jarvinen M. Long-term prognosis of patients with achilles tendinopathy. An observational 8-year follow-up study. Am J Sports Med 2000;28(5):634 642. 4. Rolf C, Movin T. Etiology, histopathology, and outcome of surgery in achillodynia. Foot Ankle Int 1997;18(9):565 569. 5. Kvist M. Achilles tendon injuries in athletes. Ann Chir Gynaecol 1991;80(2):188 201. 6. Paavola M, Kannus P, Jarvinen TA, Khan K, Jozsa L, Jarvinen M. Achilles tendinopathy. J Bone Joint Surg Am 2002;84- A(11):2062 2076. 7. Knobloch K, Kraemer R, Lichtenberg A, Jagodzinski M, Gossling T, Richter M, et al. Achilles tendon and paratendon microcirculation in midportion and insertional tendinopathy in athletes. Am J Sports Med 2006;34(1):92 97. 8. Alfredson H, Ohberg L, Forsgren S. Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. Knee Surg Sports Traumatol Arthrosc 2003;11(5):334 338. 9. Kristoffersen M, Ohberg L, Johnston C, Alfredson H. Neovascularisation in chronic tendon injuries detected with colour Doppler ultrasound in horse and man: implications for research and treatment. Knee Surg Sports Traumatol Arthrosc 2005;13(6):505 508. 10. Ohberg L, Lorentzon R, Alfredson H. Neovascularisation in Achilles tendons with painful tendinosis but not in normal tendons: An ultrasonographic investigation. Knee Surg Sports Traumatol Arthrosc 2001;9(4):233 238.
High volume image guided injections in chronic Achilles tendinopathy 1703 11. Ohberg L, Alfredson H. Ultrasound guided sclerosis of neovessels in painful chronic Achilles tendinosis: Pilot study of a new treatment. Br J Sports Med 2002;36(3):173 175. 12. Alfredson H, Ohberg L. Neovascularisation in chronic painful patellar tendinosis promising results after sclerosing neovessels outside the tendon challenge the need for surgery. Knee Surg Sports Traumatol Arthrosc 2005;13(2): 74 80. 13. Kannus P. Structure of the tendon connective tissue. Scand J Med Sci Sports 2000;10(6):312 320. 14. Sayana M, Maffulli N. Eccentric calf muscle training in nonathletic patients with Achilles tendinopathy. J Sci Med Sport 2007;10:52 58. 15. Maffulli N, Regine R, Angelillo M, Capasso G, Filice S. Ultrasound diagnosis of Achilles tendon pathology in runners. Br J Sports Med 1987;21(4):158 162. 16. Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain? Acad Emerg Med 1998;5(11):1086 1090. 17. Robinson JM, Cook JL, Purdam C, Visentini PJ, Ross J, Maffulli N, et al. The VISA-A questionnaire: A valid and reliable index of the clinical severity of Achilles tendinopathy. Br J Sports Med 2001;35(5):335 341. 18. Stanish WD, Rubinovich RM, Curwin S. Eccentric exercise in chronic tendinitis. Clin Orthop Relat Res 1986;(208):65 68. 19. Ohberg L, Lorentzon R, Alfredson H. Eccentric training in patients with chronic Achilles tendinosis: Normalised tendon structure and decreased thickness at follow up. Br J Sports Med 2004;38(1):8 11. 20. Mafi N, Lorentzon R, Alfredson H. Superior short-term results with eccentric calf muscle training compared to concentric training in a randomized prospective multicenter study on patients with chronic Achilles tendinosis. Knee Surg Sports Traumatol Arthrosc 2001;9(1):42 47. 21. Fahlstrom M, Jonsson P, Lorentzon R, Alfredson H. Chronic Achilles tendon pain treated with eccentric calf-muscle training. Knee Surg Sports Traumatol Arthrosc 2003;11(5): 327 333. 22. Roos EM, Engstrom M, Lagerquist A, Soderberg B. Clinical improvement after 6 weeks of eccentric exercise in patients with mid-portion Achilles tendinopathy a randomized trial with 1-year follow-up. Scand J Med Sci Sports 2004;14(5): 286 295. 23. Fredberg U, Bolvig L, Pfeiffer-Jensen M, Clemmensen D, Jakobsen BW, Stengaard-Pedersen K. Ultrasonography as a tool for diagnosis, guidance of local steroid injection and, together with pressure algometry, monitoring of the treatment of athletes with chronic jumper s knee and Achilles tendinitis: A randomized, double-blind, placebo-controlled study. Scand J Rheumatol 2004;33(2):94 101. 24. Richards PJ, Win T, Jones PW. The distribution of microvascular response in Achilles tendonopathy assessed by colour and power Doppler. Skeletal Radiol 2005;34(6):336 342. 25. Alfredson H, Ohberg L. Increased intratendinous vascularity in the early period after sclerosing injection treatment in Achilles tendinosis: A healing response? Knee Surg Sports Traumatol Arthrosc 2006;14(4):399 401. 26. Maffulli N, Testa V, Capasso G, Oliva F, Sullo A, Benazzo F, et al. Surgery for Chronic Achilles Tendinopathy Yields Worse Results in Nonathletic Patients. Clin J Sport Med 2006;16(2):123 128. 27. Puddu G, Ippolito E, Postacchini F. A classification of Achilles tendon disease. Am J Sports Med 1976;4(4):145 150. 28. Stone P. The implications for the conurbations of populations changes (with particular reference to London). Reg Stud 1978;12(1):95 123. 29. Cook JL, Ptazsnik R, Kiss ZS, Malliaras P, Morris ME, De LJ. High reproducibility of patellar tendon vascularity assessed by colour Doppler ultrasonography: A reliable measurement tool for quantifying tendon pathology. Br J Sports Med 2005; 39(10):700 703.
1704 O. Chan et al. Appendix Achilles Tendinopathy Questionnaire Thank-you for filling out this questionnaire about the effects of the steroid injection that you received on.......... for your Achilles tendon problems. Please answer all of the questions as this will help us to evaluate the effectiveness of the treatment and possibly improve it for future patients. Please make any comments that you feel relevant regarding the Achilles injection that you received: Please fill in the following question using the provided scales. An example is provided below. Use this approach for all following questions of this nature. Section one: Your symptoms and your sport 1. On average, how many hours per week of sport did you do before this Achilles injury? Please tick the appropriate box Less than 5 hours 5 10 hours 11 15 hours 16 20 hours More than 20 hours
2. Before this Achilles injury, what level of sport did you participate at? Please tick the appropriate box Professional Semi-Professional County Local Club Recreational Other 3. How long had your Achilles tendon been giving you problems before the injection on..........? Years Months 4. Before your injection, for how long had you had to limit your participation in sport? Years Months 5. Have you returned to sport since the injection? Please tick the appropriate box High volume image guided injections in chronic Achilles tendinopathy 1705 6. How would you describe the overall recovery of your Achilles/ankle problem? Please tick the appropriate box Back to normal and stayed better Got better then recurred Slightly better but not back to normal Never improved Other (Please specify) 7. What percentage of the total improvement in your symptoms do you attribute to the injection? Section two: Previous medical management 8. How many clinicians had you seen with this problem prior to the injection? Put a number in the box next to each professional group. Doctor Physiotherapist Surgeon Osteopath Masseur Other (Please specify) 9. Prior to your injection, what other treatments had you tried/received? Please tick all the appropriate boxes Orthotics Physiotherapy Strapping Surgery Massage Other injection Medication (Please specify) 10. Have you done specific eccentric re-training guided by a physiotherapist? This would include slow heel lowering off the edge of a step and similar exercises for about six weeks. Yes No
1706 O. Chan et al. 11. Which of the following investigations have you received for your Achilles problem? Please tick all the appropriate boxes Blood Tests X-ray CT Scan MRI Scan Ultrasound Scan Arthroscopy Other (Please specify) Section three: Pain 12. Which 3 activities gave you the most pain in your Achilles/ankle prior to your injection? Please use the scale below to rate the pain on doing each these activities 2 weeks before and 2 weeks after the injection. Activity 1 Activity 2
High volume image guided injections in chronic Achilles tendinopathy 1707 Activity 3 13. What would you rate the pain score as being in your Achilles/ankle in the last two weeks? Section four: Function 14. Which 3 activities did you find it most difficult or impossible to do because of the symptoms (e.g. weakness, loss of balance, pain etc) in your Achilles/ankle prior to your injection? Activity (1)
1708 O. Chan et al. Activity (2) Activity (3) Section 5: Comments Finally, please add any comments about:- Thank you for filling in this questionnaire. This will help us improve our treatment for patients with Achilles tendon problems.